Clinical trials: Locally Advanced Gastric Cancer, open to volunteers
Adebrelimab (SHR-1316), XELOX
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric cancer/adenocarcinoma of the gastroesophageal junction.
- Conditions
- Adebrelimab (SHR-1316), XELOX, GC/GEJC
- Trial name
- NCT06506292
- Testing
- Adebrelimab, XELOX
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Stomach Neoplasms
Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
CLASS-07 trial is a prospective, multicenter, randomized controlled trial for comparison of long-term outcomes between laparoscopic total gastrectomy (LTG) and open total gastrectomy (OTG) in patients with locally advanced…
- Trial name
- CLASS-07 (NCT04710758)
- Testing
- Laparoscopic total gastrectomy, Open total gastrectomy
- Where
- China
- Volunteers
- 1,018 people
- Sponsor
- Shanghai Zhongshan Hospital
Stomach Neoplasm
Laparoscopic vs. Open Distal Gastrectomy After Neoadjuvant Chemotherapy
The study was designed as single-country, multi-center, open-labelled, randomized (1:1), phase II trial. 238 patients with medically and technically operable advanced gastric adenocarcinoma in middle or distal 1/3 of stomach are…
- Trial name
- NCT04658589
- Testing
- Laparoscopic versus open distal gastrectomy
- Volunteers
- 238 people
- Sponsor
- Chonnam National University Hospital
Gastric Cancer (GC), No.4sb
The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
The main purpose of this study is to evaluate the reasonable range of No.4sb lymph node dissection of locally advanced distal gastric cancer.
- Trial name
- Range of 4sb (NCT07183150)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer (GC), Locally Advanced Gastric Cancer
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy.
- Trial name
- NCT07401199
- Testing
- Standard of Care PD-1 Inhibitors, Multimodal AI Assessment
- Where
- 9 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Qun Zhao
Gastric Adenocarcinoma
Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
This is a single-center, single-arm, phase 2 clinical study testing a new neoadjuvant (pre-surgery) treatment for patients with locally advanced gastric cancer or gastroesophageal junction (GEJ) cancer.
- Trial name
- NCT07867392
- Testing
- Iparomlimab and Tuvonralimab (QL1706), nab-P-SOX（nab-paclitaxel, oxaliplatin, S-1）
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced…
- Conditions
- Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
- Trial name
- YOUNG-NEOS (NCT07018063)
- Testing
- nab-paclitaxel, oxaliplatin, S-1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- zhoujing
Gastric Cancer, Adenocarcinoma
Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
The purpose of this clinical trial is to investigate whether the drug Shenqi Fuwei Mixture is effective for postoperative recurrence and metastasis of gastric cancer. Safety of Shenqi Fuwei Mixture will also be understood.
- Trial name
- NCT07098026
- Testing
- Shenqi Fuwei Mixture
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Hunan Cancer Hospital
Gastric Adenocarcinoma
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
This study is a multicenter, randomized, two-cohort clinical trial to evaluate the efficacy and safety of SHR-1701 with or without apatinib in combined with chemotherapy of neoadjuvant treatment for resectable locally advanced…
- Trial name
- NCT07464756
- Testing
- SHR-1701, apatinib, S-1 & Oxaliplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Advanced Gastric Cancer
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC).
- Trial name
- Neo-D2plus (NCT03961373)
- Testing
- Gastrectomy with D2 lymphadenectomy, Gastrectomy with D2plus lymphadenectomy
- Where
- Italy
- Volunteers
- 539 people
- Sponsor
- University of Siena
Locally Advanced Gastric Cancer, Gastric Adenocarcinoma
HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
Patients with locally advanced gastric cancer (LAGC), particularly those with serosal invasion, remain at high risk of peritoneal recurrence despite standard perioperative treatment.
- Conditions
- Locally Advanced Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07621484
- Testing
- Hyperthermic Intraperitoneal Chemotherapy, Serplulimab, S-1
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Changzheng Hospital
Locally Advanced Unresectable or Metastatic Gastric Cancer
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer…
- Trial name
- NCT07547787
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Akeso
Solid Tumor, Advanced Cancer
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma).
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
- Trial name
- NCT07432295
- Testing
- Givastomig, Nivolumab, 5Fluorouracil
- Where
- 6 sites in United States, China and 1 more
- Volunteers
- 180 people
- Sponsor
- I-Mab Biopharma US Limited
Locally Advanced Cancer, Metastatic Cancer
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
The purpose of this study is to determine if the radiotracer, [68Ga]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+…
- Conditions
- Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06828588
- Testing
- [68Ga]Ga-ABY-025
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Gastric Cancer
Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer
This study was a prospective, single-arm, multi-center, phase Ⅱ clinical study to investigate the efficacy and safety of ipilimumab injection N01 combined with sintilimab and modified XELOX conversion therapy in patients with…
- Trial name
- DIAMC-GC (NCT07638631)
- Testing
- Ipilimumab injection N01, Sintilimab, Modified (60% standard dose) XELOX
- Volunteers
- 30 people
- Sponsor
- Chen Lizhu
Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor…
- Conditions
- Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
- Trial name
- NCT07554521
- Testing
- Tislelizumab, Capecitabine, 5-fluorouracil (5-FU)
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Gastroesophageal Junction Cancer, Stomach Neoplasms
Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer
This multicenter prospective randomized clinical trial aims to compare the safety and oncological effectiveness of proximal gastrectomy and total gastrectomy in patients with locally advanced Siewert type II-III gastroesophageal…
- Conditions
- Gastroesophageal Junction Cancer, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- SIEWERT-RCT (NCT07482566)
- Testing
- Proximal Gastrectomy, Total Gastrectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Nurettin Şahin
Locally Advanced Gastric Cancer
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
To evaluate the clinical efficacy of albumin paclitaxel combined with carelizumab and FLOT in the neoadjuvant treatment of locally advanced gastric cancer with different immune types
- Trial name
- NCT05610332
- Testing
- Camrelizumab, Albumin Taxol, FLOT scheme
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Fujian Medical University
Gastric Adenocarcinoma
A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
An open-label, randomized, comparative phase II study including patients with CLDN18.2-positive unresectable locally advanced gastric cancer.
- Trial name
- NCT07103668
- Testing
- CAR T cells, Control
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Gastric Junction Adenocarcinoma, Gastric Cancer
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
The goal of this clinical trial is to learn if sorbitol works to enhance the therapeutic effect of neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) in patients with locally advanced gastric cancer.
- Conditions
- Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy, Neoadjuvant Therapies
- Trial name
- SNCCTGC (NCT06826079)
- Testing
- Sorbitol + PD-1 inhibitor + SOX chemotherapy, PD-1 inhibitor + SOX chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology